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Lower genital tract infection or blood borne spread of infection are the two 
principal modes for infection of the upper genital tract or for infection of the fetus, 
neonate or infant. Treponema pallidum or human immunodeficiency virus are the 
two most common blood borne pathogens that infect the fetus, neonate or infant. 
Most infections of the upper genital tract however spread along epithelia surfaces 
from the vagina or cervix to the upper genital tract or chorioamnion, fetus, neonate 
or infant. These infections are caused by either pathogens associasted with a 
dysbiotic vaginal microbiome or which are sexually transmitted. The clinical 
syndromes that these pathogens produce in the lower genital tract were discussed 
in part one of this review. We now discuss the syndomes and pathogens that affect 




The reproductive system perspective is most helpful in understanding the 
variety of infectious disease syndromes which occur in the upper genital tract of 
non-pregnant and pregnant women despite the fact that the specific pathogens are 
the same. We now review those upper genital tract syndromes. 
 
Endometrium, Fallopian Tube and Ovaries 
 
 Ascending infection from the vagina or cervix cause most cases of acute and 
subclinical pelvic inflammatory disease. Pelvic inflammatory disease is the major 















Pelvic Inflammatory Disease, Tubal Infertility and Ectopic Pregnancy 
 
 Pelvic inflammatory disease can spontaneously ascend from vaginal and 
cervical infection or follow therapeutic abortion or childbirth. Pelvic inflammatory 
disease can be classified as acute (< 30 days duration), subclinical or chronic 1. Acute 
pelvic inflammatory disease is defined as complaints of lower abdominal pain 
together with findings of pelvic organ tenderness, on bimanual examination and 
with signs of lower genital tract inflammation such as endocervical mucopus and/or 
excess neutrophils (outnumbering squamous epithelial cells) in microscopic 
examination of vaginal fluid. Sexually transmitted cervical pathogens such as 
Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium2 which 
are important causes of mucopurulent cervicitis are major causes of acute and 
subclinical pelvic inflammatory disease. Organisms associated with bacterial 
vaginosis and desquamative inflammatory vaginitis as part of dysbiotic vaginal 
microbiomes are also important causes of pelvic inflammatory disease. Both vaginal 
and cervical pathogens spread contiguously from the lower genital tract to the 
endometrium and fallopian tubes where they cause plasma cell endometritis3, 4. 
Bacterial vaginosis organisms as they spread into the upper genital tract also 
produce a dense biofilm on the endometrial epithelial surface5.  
 Acute pelvic inflammatory disease clinically responds to a variety of 
antimicrobial agents6 and recommended treatments for pelvic inflammatory disease 
have been standardized by several public health organizations including the Centres 
for Disease Control and Prevention in the United States. Systematic meta analysis of 
recommended antimicrobial regimens show that no regimen is superior in terms of 
clinical and microbiologic responses7. However long-term reproductive disability 
remains distressingly high following treatment of pelvic inflammatory disease with 
15% or more of women suffering from recurrent pelvic inflammatory disease or 
tubal infertility1. No antimicrobial regimen has been demonstrated to be superior in 
reducing the risk of post infection sequelae. The reasons for the dismal outcomes 
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damage to the delicate structures of the fallopian tube prior to therapy. Future trials 
of antimicrobial therapies for pelvic inflammatory disease need to include long-term 
evaluation of determinants of post pelvic inflammatory disease sequelae such 
recurrent pelvic inflammatory disease, tubal infertility and ectopic pregnancy. One 
study that used this type of design noted that polymicrobial tubal infection with 
abscess formation or Chlamydia trachomatis pelvic inflammatory disease had 
significantly worse fertility outcome than women with gonococcal pelvic 
inflammatory disease8. In large seroepidermiologic studies rates of pregnancy were 
significantly lower and pelvic inflammatory disease recurrence rates were 
significantly higher among women with high titers of Chlamydia trachomatis 
antibodies than those without such antibodies among a cohort of women treated for 
pelvic inflammatory disease suggesting that Chlamydia trachomatis pelvic 
inflammatory disease carries a worse fertility prognosis than other causes of pelvic 
inflammatory disease9.  
Since Chlamydia trachomatis is such an important cause of pelvic 
inflammatory disease and sequelae it has been studied in considerable detail from 
epidemiologic, genomic and immunological points of view. Epidemiological analysis 
suggests that both duration of infection and reinfection are important in Chlamydia 
trachomatis pelvic inflammatory disease pathogenesis10-12. Immunoepidemiologic 
studies suggest that antibodies to Chlamydia trachomatis molecular components 
such as Chlamydia trachomatis heat shock protein 60 correlate with sequelae such 
as tubal infertility, ectopic pregnancy, pelvic inflammatory disease and perihepatitis 
perhaps as a marker of long duration infection13-18. It is unlikely that Chlamydia 
trachomatis heat shock protein 60 is directly involved in disease pathogenesis9. 
Rather antibody responses to Chlamydia trachomatis heat shock protein 60 are co-
linear with antibody to the whole Chlamydia trachomatis bacterial cell. Heat shock 
protein 60 is a single molecule measure of immune responses to persistent 
Chlamydia trachomatis infection because of its immunodominance during long 
duration infection19. In aggregate immunoepidemiological studies of Chlamydia 
trachomatis heat shock protein 60 show that antibody dominant immune responses 
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Dominant interferon gamma or IL-10 cellular immune responses to Chlamydia 
trachomatis heat shock protein 60 correlate with protection to infection or 
susceptibility to immunopathology20, 21. Since humoral and cellular immune 
responses to heat shock protein 60 are reciprocally related it is possible that genetic 
factors that regulate Th1 versus Th2 immune responses determine Chlamydia 
trachomatis immunobiology. 
Both ectopic pregnancy and tubal infertility are seroepidemiologically linked 
to prior Chlamydia trachomatis pelvic inflammatory disease. Most cases involve 
subclinical pelvic inflammatory disease. Histopathologically the fallopian tube of 
women with Chlamydia trachomatis associated ectopic pregnancy is characterized 
by plasma cell infiltration without evidence of ongoing infection13-15. In Africa where 
tubal infertility is especially common prior Chlamydia. trachomatis and Neiserria 
gonorrhoeae pelvic inflammatory disease are serologically linked with tubal 
infertility and predominantly occurs among women who previously gave birth22. In 
these settings Chlamydia trachomatis and Neiserria gonorrhoeae infections are 
common and public health control programs for maternal care are often not in 
place. As a consequence parturition is a major cause of ascending Chlamydia 
trachomatis and Neissera gonorrhoeae infection resulting in post partum 
endometritis, pelvic inflammatory disease and secondary infertility23, 24. Ophthalmia 
neonatorum is the major marker for mothers at risk of post partum pelvic 
inflammatory disease25. Screening and treatment for Chlamydia trachomatis and 
Neisseria gonorrhoeae in pregnancy substantially reduces the risk of post partum 




 Pelvic inflammatory disease may be a risk factor for ovarian cancer. 
Inflammation has been suggested as a causal link between pelvic inflammatory 
disease and ovarian cancer26, 27. Seroepidemiologic studies have linked prior 
Chlamydia trachomatis infection with ovarian cancer although the association has 
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double strand DNA breaks in infected host cells a casual pathway may exist where 
Chlamydia trachomatis infection of fallopian tube epithelial cells acts as a co-factor 
together with other inflammatory oncogenic factors in the genesis of ovarian 
cancer31.  
 
Chorioamnion, Fetus, Neonate and Infant 
 
 Reproductive system infections during pregnancy rarely result in pelvic 
inflammatory disease. Rather ascending infection most commonly infects the 
chorioamnion and fetus or transmits during birth to cause disease in the neonate or 
infant. The major diseases produced by infection are chorioamnionitis and 
prematurity, stillbirth and neonatal and infant infection. 
 
Chorioamnionitis and Prematurity 
 
Chorioamnionitis is pathologically defined as inflammation of the fetal 
membranes and is the single most important risk factor for preterm birth and can be 
subclinical or clinical in presentation32. Chorioamnionitis is also the major risk 
factor for neonatal sepsis and death33. Organisms associated with bacterial vaginosis 
(Gardnerella vaginalis, Mobiluncus sp., Bacteroides sp. etc) and the vaginal dysbiosis 
associated with desquamative inflammatory vaginitis (group B Streptococci, 
Escherichia coli etc) are commonly isolated from fetal membranes when 
chorioamnionitis is found pathologically34. Treatment during later months of 
pregnancy for bacterial vaginosis does not prevent preterm birth whereas 
treatment during early pregnancy may do so35. Intrapartum antimicrobial treatment 
for group B Streptococci reduces the risk of neonatal sepsis due to this microbe. 
Intrapartum gonococcal infection is also a major cause of pre term birth in areas 
















Intrauterine fetal death can result from maternal reproductive system 
infection. Blood borne spread of human immunodeficiency virus or syphilis to the 




Maternal infection with Chlamydia trachomatis or Neisseria gonorrhoeae 
frequently results in ophthalmia neonatorum36, 38. Thirty to 40% of neonates 
exposed to Chlamydia trachomatis or Neisseria gonorrhoeae intrapartum become 
infected postpartum39. Neonates with gonococcal ophthalmia neonatorum can be 
successfully treated with antimicrobials including ceftriaxone40, 41. Ocular 
prophylaxis dramatically reduces the incidence of gonococcal and chlamydial 
ophthalmia neonatorum42. Neonates exposed during birth to maternal Chlamydia 
trachomatis infection are also at increased risk of developing infant pneumonia43. All 
these risks for neonatal and infant infectious disease can be prevented by maternal 




 Viewing reproductive system infections in women as encompassing diseases 
of the vulva, vagina, cervix, endometrium, fallopian tubes and ovaries and the 
chorioamnion, fetus, neonate and infant shows how they share common 
epidemiology, microbial etiologies and pathogenic mechanisms. The syndrome, 
etiologic agent, treatment and prevention modalities are summarized in table 1.  
Existing disease control programs based on screening and treatment remain 
effective and important in improving the reproductive health of women. The impact 
of the absence of reproductive health services is seen in epidemiological settings 









ulib user on 08 June 2020
 
 
tubal factor infertility is tragically common, maternal syphilis or human 
immunodeficiency virus infection increase stillbirth rates 3 to 5 fold and 3 to 5 % of 
newborns develop gonococcal or chlamydial ophthalmia neonatorum. In particular 
screening and treatment for Chlamydia trachomatis and Neisseria gonorrhoeae, 
syphilis and human immunodeficiency virus substantially improves the 
reproductive health of women as well as reduces the risk of fetal, neonatal and 
infant disease. Ocular prophylaxis at birth prevents ophthalmia neonatorum. Rolling 
out and supporting these programs at a global level is a major goal for global health 
programs best done within a comprehensive reproductive system framework. 
An important realization has been that control programs for the bacterial 
sexually transmitted pathogens profoundly alter the clinical features and patterns of 
disease. Because of the extended duration of time post infection that it takes to 
acquire immunity to these pathogens, shortening the duration of infection by 
screening and antimicrobial treatment reduces herd immunity and shifts the clinical 
features of infection towards subclinical infection. Thus disease control programs 
based on screening and antimicrobial treatment have important limits. The major 
sexually transmitted bacterial pathogens Chlamydia trachomatis, Neisseria 
gonorrhoeae and Treponema pallidum will require vaccines to fully achieve control. 
Fortunately molecular study of these pathogens has generated promising candidates 
that can soon be brought forward for clinical evaluation as was successfully done for 
human papilloma virus. Vaccines are at the forefront of research to prevent 
reproductive system infections of women. 
 Despite advancements in understanding reproductive system infections in 
women much remains incompletely known. For instance the causes of vulvar 
vestibulitis need to be understood at a microbial and immunological level because it 
is such a common cause of painful intercourse. An understanding of the cause of 
recurrent vulvovaginal candidiasis may well improve prevention of vulvar 
vestibulitis. Why a Lactobacilli dominant microbiome is lost in some women 
resulting in susceptibility to bacterial vaginosis , trichomoniasis and desquamative 
inflammatory vaginitis needs to be understood. Diagnostic test development is 









ulib user on 08 June 2020
 
 
molecular tests for the microbial composition of the vaginal microbiome would 
improve the recognition of bacterial vaginosis, desquamative inflammatory 
vaginitis, trichomoniasis and candidiasis. Additionally improved imaging modalities 
of the uterus, fallopian tubes and ovaries would advance diagnosis of clinical and 
subclinical pelvic inflammatory disease and its sequelae. Current evidence suggests 
that magnetic resonance imaging has the resolution necessary to image the pelvis 
including the fallopian tubes and should be used in future studies of pelvic 
inflammatory disease44, 45. Lastly tests that diagnose subclinical chorioamnionitis 
have the potential to have a major impact on preterm birth46, 47. 
  Recurrent infection remains a major problem for reproductive system 
infection in women. Randomized clinical trials using antimicrobials, sex steroids and 
immune modulators for vulvar vestibulitis, bacterial vaginosis, desquamative 
inflammatory vaginitis, vulvovaginal candidiasis and pelvic inflammatory disease 
may lead to therapies which reduce relapse rates and/or post disease sequelae. 
Strategies that stabilize a Lactobacilli vaginal microbiome may prevent recurrences 
of bacterial vaginosis, desquamative inflammatory vaginitis and protect against a 
broad variety of sexually transmitted pathogens. Strategies that enhance the 
proportion of male sexual partners who are treated will be particularly important to 
reducing recurrence rates for the sexually transmitted pathogens.  
 Additional antimicrobial interventions in pregnancy are needed to address 
the continuing problem of prematurity. It is remarkable that despite the continuing 
im provement in survival of neonates born prematurely the rates of prematurity 
have not changed. The impact of treatment of vaginal dysbiosis in pregnancy on 
preterm birth remains incompletely defined. Treatment of bacterial vaginosis in late 
pregnancy does not prevent preterm birth however treatment in early pregnancy 
may do so35. Studies should focus on early interventions, use of probiotics with 
antimicrobials and evaluate effects on both preterm birth and histopathologic 
evidence of chorioamnionitis. Given the propensity of bacterial vaginosis to produce 
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 Two Nobel Prizes in Medicine and Physiology have been awarded to 
scientists for advances they have made in women’s reproductive health. In 2008, 
Nobel Prizes were awarded to Harald zur Hausen for the discovery of human 
papilloma viruses causing cervical cancer and to Francoise Barre-Sinoussi and Luc 
Montagnier for their discovery of the human immunodeficiency virus. In 2010 the 
Nobel Prize was given to Robert Edwards for the development of human in vitro 
fertilization therapy initially used in the treatment of post pelvic inflammatory 
disease tubal infertility.  Despite the awarding of Nobel Prizes, this class of infectious 
diseases remains under-studied, under-appreciated, under-diagnosed and 
inconsistently treated. Future research which addresses the major questions are 
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